Author:
Buzlea<#%##> Călin,Noor<#%##> Hassan,Micu Alexandra,Vîlceanu Ioana,Pirvut<#%##> Valentin
Reference54 articles.
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
2. Keyes M, Crook J, Morton G, Vigneault E, Usmani N, Morris WJ. Treatment options for localized prostate cancer. Can Fam Physician. 2013;59(12):1269-74.
3. Incrocci L. Radiotherapy for prostate cancer and sexual health. Transl Androl Urol. 2015;4(2):124-30.
4. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737-46.
5. Chen L, Qiu X, Wang R, Xie X. The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: A systematic review. Sci Rep. 2014;4:4818.